ABSTRACT
PURPOSE: While the HeartWare® Ventricular Assist System (HVAS) is a successful therapy for end-stage heart failure, outpatient management methods can vary significantly and require further investigation. METHODS: A survey to assess the long-term HVAS patient management and monitoring strategies was completed by 36 international heart centers that currently have over 1,450 patients on VAD support either at home or in the hospital. Multiple choice questions examined VAD program characteristics, anticoagulation management, driveline exit-site dressing and showering recommendations, blood pressure and pump parameter monitoring, and patient discharge protocols. RESULTS: Outpatient international normalized ratio (INR) was most frequently measured every 3-4 days (28.6%), and the most frequent schedule for changing driveline exit site dressings was 3 times per week (30.6%). Only 25.7% of centers required their patients to measure blood pressure at home. A subgroup analysis was performed to assess the influence of center experience and larger centers generally had more frequent monitoring compared to smaller centers. CONCLUSIONS: This survey showed specific differences in outpatient management strategies that were previously unreported. However, further studies with correlations to patient outcomes are necessary to determine optimal patient management recommendations.
Subject(s)
Ambulatory Care/statistics & numerical data , Heart-Assist Devices , Blood Pressure Monitoring, Ambulatory/statistics & numerical data , Cardiac Care Facilities , Heart Failure/therapy , Humans , International Normalized Ratio , Surveys and Questionnaires , Telemetry/statistics & numerical dataABSTRACT
During the period 1998-2004, candidemia developed in 7 of 117 ventricular assist device recipients at our hospital, and the associated mortality rate was 71%. Five cases of candidemia were due to Candida parapsilosis, and 2 were due to Candida albicans. Three of the 7 patients with ventricular assist device-associated Candida bloodstream infections were cured, and the device was retained in 2 of the 3 patients.
Subject(s)
Candidiasis/etiology , Fungemia/etiology , Heart-Assist Devices/adverse effects , Antifungal Agents/therapeutic use , Candidiasis/drug therapy , Candidiasis/mortality , Case-Control Studies , Female , Fungemia/drug therapy , Fungemia/mortality , Humans , Male , Middle Aged , Odds Ratio , Retrospective Studies , Risk FactorsABSTRACT
A 45-year-old man had life-threatening recurrent idiopathic ventricular fibrillation and persistent cardiogenic shock develop. The episodes of ventricular fibrillation were refractory to aggressive medical management; therefore an Abiomed AB5000 bi-ventricular support system was implanted for arrhythmia control. The device was able to maintain hemodynamic stability during the following 2 weeks. The patient was discharged from the hospital with fully recovered cardiac function.
Subject(s)
Heart-Assist Devices , Ventricular Fibrillation/surgery , Humans , Male , Middle Aged , Ventricular Fibrillation/physiopathologyABSTRACT
Long-term outcomes after coronary artery bypass graft surgery (CABG) plus transmyocardial revascularization (TMR) are largely unknown. We report the results of 30-day and 3-, 6-, and 12-month clinical follow-up after CABG plus TMR in a consecutive series of patients with refractory angina pectoris and > or = 1 myocardial ischemic area not amenable to CABG. All patients who underwent CABG plus TMR (n = 169) (mean age 63 +/- 10 years, 70% men, 51% with previous CABG, 82% were deemed inoperable at other heart surgery centers due to small vessels or diffuse disease) between March 1996 and February 2000 were clinically followed and end points of interest (survival, stroke, acute myocardial infarction, and revascularization) and angina class were recorded at 30 days and 3, 6, and 12 months after CABG. At 1 year, actuarial survival and event-free survival were 85% and 81%, respectively. At the end of the first year after the procedure, 7 patients (4%) had angina class III/IV versus 152 patients (90%) at baseline (p <0.001). Predictors of major adverse cardiac events were advanced age (odds ratio [OR] 3.4, 95% confidence intervals [CI] 1.2 to 9.4, p = 0.01), prolonged intensive care unit stay (OR 3.3, CI 1.1 to 9.7, p <0.001), new-onset atrial fibrillation (OR 2.8, CI 1.1 to 7.0, p = 0.02), and in-hospital myocardial infarction (OR 1.5, CI 1.3 to 1.7, p <0.001). Thus, procedural success at 30 days and overall event-free and actuarial survival in a high-risk population setting shows that CABG plus TMR is a safe revascularization option for patients with intractable angina pectoris.
